OncLive TV

Branko Cuglievan, MD, discusses data for revumenib in the pediatric R/R KMT2AR-acute leukemias subgroup from AUGMENT-101.

Pavlos Msaouel, MD, PhD, discusses the rationale for examining panitumumab-based treatment in SMARCB1-deficient RMC.

Jennifer Marvin-Peek, MD, discusses data for azacitidine, venetoclax, and ivosidenib, in IDH1-mutated acute myeloid leukemia and their significance.

Vincent Picozzi, MD, discusses the FDA approval of Optune Pax for locally advanced pancreatic cancer and the criteria for optimal patient selection.

Mark D. Tyson, II, MD, MPH, discusses how TARA-002 could fit into the treatment landscape of BCG-naive NMIBC.

Jiong Wu, MD, PhD, discusses the significance of studying iza-bren in a phase 3 setting in unresectable, locally advanced or metastatic TNBC.

Glenn J. Hanna, MD, highlights interim efficacy and safety data from a phase 1 trial of Emi-Le in patients with aggressive adenoid cystic carcinoma.

Mark A. Socinski, MD, discusses data from stage 1 of the phase 3 PRESERVE-003 trial (NCT05671510) in patients with squamous NSCLC.

Marwan G. Fakih, MD, discusses how data from the POD1UM-303 trial support the use of retifanlimab in frontline squamous cell anal carcinoma.

Mark D. Tyson, II, MD, MPH, discusses efficacy data with TARA-002 in patients with BCG-naive high-grade non–muscle-invasive bladder cancer.

Daniel Olson, MD, discusses findings with brenetafusp from a phase 1/2 trial (NCT04262466) in patients with advanced melanoma.

Frederick Howard, MD, outlines limitations and opportunities for AI in breast pathology, shifting focus from workflow efficiency to prognostic value.

Elena Elimova, MD, discusses data from a HERIZON-GEA-01 PD-L1 subgroup analysis in HER2-positive gastroesophageal adenocarcinoma.

Matthew Galsky, MD, discusses the present and future use of biomarkers in bladder cancer.

Brad Haverkos, MD, discusses approaches for the management of mogamulizumab-associated rash in patients with cutaneous T-cell lymphoma.

Sonali M. Smith, MD, discusses implications of data for tafasitamab plus lenalidomide/R-CHOP in high-risk diffuse large B-cell lymphoma.

Cara A. Mathews, MD, discusses the updated findings from cohort D2 of the phase 1/2 RAINFOL-01 trial (NCT05579366) in advanced ovarian cancer.

Nan Chen, MD, discusses ADC-associated toxicity management in breast cancer, as well as the evolving role of oral SERDs in ER-positive disease.

Raj Singh, MD, highlighted the importance of multidisciplinary collaboration in brain cancer management in observance of World Brain Tumor Day.

Heather Leeper, MD, discussed ideal survivorship care for geriatric patients with brain cancer.

Matthew Galsky, MD, discusses the emergence of ICIs the neoadjuvant setting of bladder cancer.

Geoffrey Ku, MD, discusses data from HERIZON-GEA-01 showing zanidatamab plus tislelizumab benefits patients with HER2-positive GEA regardless of PD-L1 status.

Matthew Galsky, MD, discusses the standing of immune checkpoint inhibitors in bladder cancer.

Matthew Galsky, MD, disusses how the treatment paradigm of bladder cancer has shifted over time.

Gerald Soff, MD, discusses data from the phase 3 RECITE trial showing that romiplostim reduces chemotherapy dose modifications in patients with GI cancer.

Jennifer Eads, MD, discusses data for the CAR T-cell therapy CHM-2101 in relapsed/refractory GI cancers.

John Mascarenhas, MD, discusses key data from the SENTRY trial of selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis.

Tycel Phillips, MD, discusses the FDA approval of sonrotoclax in mantle cell lymphoma and where the agent can be best applied in the treatment paradigm.

Linda R. Mileshkin, MBBS, FRACP, Mbioeth, highlights efficacy data with puxitatug samrotecan in patients with ovarian and endometrial cancers.

Tony Mok, BMSc, MD, FRCPC, FHKCP, FHKAM, FRCP, notes the implications of 7-year data from the CROWN study of frontline lorlatinib in ALK-positive NSCLC.